Acute effects of dietary fat on inflammatory markers and gene expression in first-degree relatives of type 2 diabetes patients [0.03%]
膳食脂肪对2型糖尿病患者一级亲属炎症标志物和基因表达的急性影响
Anna Pietraszek,Søren Gregersen,Kjeld Hermansen
Anna Pietraszek
Background: Subjects with type 2 diabetes (T2D) and their relatives (REL) carry an increased risk of cardiovascular disease (CVD). Low-grade inflammation, an independent risk factor for CVD, is modifiable by diet. Subject...
Health care access and prevalence of the metabolic syndrome among elders living in high-altitude areas of the Mediterranean islands: the MEDIS study [0.03%]
地中海岛屿高海拔地区的老年人代谢综合征患病率及其影响因素：MEDIS研究
Stefanos Tyrovolas,Christos Chalkias,Marianthi Morena et al.
Stefanos Tyrovolas et al.
Aim: The aim of the present work was to evaluate the relationships between sociodemographic, clinical, and lifestyle characteristics and the presence of metabolic syndrome, among high and low altitude living elderly indiv...
Comparative Study
The review of diabetic studies : RDS. 2011 Winter;8(4):468-76. DOI:10.1900/RDS.2011.8.468 2011
Simon E Regnell,Åke Lernmark
Simon E Regnell
Islet autoimmunity in type 1 diabetes results in the loss of the pancreatic β-cells. The consequences of insulin deficiency in the portal vein for liver fat are poorly understood. Under normal conditions, the portal vein provides 75% of th...
Angela D Mazza,Richard E Pratley,Steven R Smith
Angela D Mazza
Obesity is associated with an increased risk of type 2 diabetes (T2D). Pancreatic beta-cell failure is an early event in the development of glucose dysregulation and diabetes. Interventions to halt beta-cell failure in T2D include diet modi...
Metabolic memory and individual treatment aims in type 2 diabetes--outcome-lessons learned from large clinical trials [0.03%]
2型糖尿病的代谢记忆及个人治疗目标——大型临床试验的结果与启示
Cristina Bianchi,Stefano Del Prato
Cristina Bianchi
Reducing the burden of long-term complications in type 2 diabetic patients remains a major task, and represents a huge challenge. Whilst tight glycemic control has been shown to reduce the risk of microvascular complications, controversy re...
Cendrine Cabou,Rémy Burcelin
Cendrine Cabou
Glucagon-like peptide 1 (GLP-1) is a gut hormone which directly binds to the GLP-1 receptor located at the surface of the pancreatic β-cells to enhance glucose-induced insulin secretion. In addition to its pancreatic effects, GLP-1 can ind...
Maria A Guzzardi,Patricia Iozzo
Maria A Guzzardi
Type 2 diabetes and obesity are associated with systemic inflammation, generalized enlargement of fat depots, and uncontrolled release of fatty acids (FA) into the circulation. These features support the occurrence of cardiac adiposity, whi...
Hiddo J Lambers Heerspink,Dick de Zeeuw
Hiddo J Lambers Heerspink
Renal and cardiovascular complications make type 2 diabetes one of the most morbid conditions in medicine. The kidney frequently gets involved in this "multi-organ disease". Of the large proportion of patients who progress with further loss...
Michael Lehrke,Nikolaus Marx
Michael Lehrke
GLP-1-modulating therapies are a class of anti-diabetic drugs that improve glycemic control by stimulating glucose-dependent insulin secretion from pancreatic beta-cells. In addition, GLP-1-based therapies have a variety of extrapancreatic ...
Mikkel Christensen,Jonatan I Bagger,Tina Vilsbøll et al.
Mikkel Christensen et al.
Glucagon is the main secretory product of the pancreatic alpha-cells. The main function of this peptide hormone is to provide sustained glucose supply to the brain and other vital organs during fasting conditions. This is exerted by stimula...